



US006506422B1

(12) **United States Patent**  
**Masson et al.**

(10) **Patent No.: US 6,506,422 B1**  
(45) **Date of Patent: \*Jan. 14, 2003**

(54) **NUTRITIONAL FORMULA FOR  
PHENYLKETONURIA PATIENTS**

(75) Inventors: **Gérard Masson**, Cully (CH); **Julio Cesar Monti**, Jongny (CH); **Olivier Ballevre**, Lausanne (CH)

(73) Assignee: **Nestec S.A.**, Vevey (CH)

(\*) Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 51 days.

(21) Appl. No.: **09/242,746**

(22) PCT Filed: **Aug. 25, 1997**

(86) PCT No.: **PCT/EP97/04761**

§ 371 (c)(1),

(2), (4) Date: **Feb. 22, 1999**

(87) PCT Pub. No.: **WO98/08402**

PCT Pub. Date: **Mar. 5, 1998**

(30) **Foreign Application Priority Data**

Aug. 30, 1996 (EP) ..... 96202419

(51) **Int. Cl.<sup>7</sup>** ..... **A23C 11/02**

(52) **U.S. Cl.** ..... **426/2; 426/656; 426/801; 424/442**

(58) **Field of Search** ..... **426/801, 2, 656; 424/442**

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,216,129 A	6/1993	Berrocal et al.	
5,225,238 A	7/1993	Ardaillon et al.	
5,393,532 A *	2/1995	Wachtel et al.	426/656
5,411,757 A	5/1995	Buist et al.	

**FOREIGN PATENT DOCUMENTS**

DE	2 117 243	5/1973	
EP	0 492 183	7/1992	
EP	492183	* 7/1992	426/801
GB	2 223 925	4/1990	
JP	8165-742	* 9/1983	426/801
JP	59-51111	3/1984	
JP	61-152523	7/1986	
JP	40-4126051 A *	9/1990	
JP	04126051	* 4/1992	
JP	04-126051	4/1992	
WO	WO 85/03230	8/1985	
WO	94/15952	* 7/1994	
WO	WO 94/17789	8/1994	

**OTHER PUBLICATIONS**

"Casein Macropeptide from Whey—A New Product Opportunity", Food Research Quarterly, vol. 51, Nos. 1 & 2, 1991.

"The Justification Theory: The Essential Nature of the Non-Essential Amino Acids", Nutritional Reviews, vol. 37, No. 7, Jul. 1979.

"Increased Neurotransmitter Biosynthesis in Phenylketonuria Induced by Phenylalanine Restriction or by Supplementation of Unrestricted Diet with Large Amounts of Tyrosine", Eur. J. Pediatr. (1988): 238-245.

"Cognition and Tyrosine Supplementation Among School-Aged Children with Phenylketonuria", AJDC, vol. 146, Nov. 1992.

"Increased Vigilance and Dopamine Synthesis by Large Doses of Tyrosine or Phenylalanine Restriction in Phenylketonuria", Acta Paediatr. Scand., 76: 560-565, 1987.

"Phenylketonuria Due to Phenylalanine Hydroxylase Deficiency: An Unfolding Story", BMJ, vol. 306, Jan. 1993.

"Clinical Trial of a Concentrated Amino Acid Formula for Older Patients with PKU", E. J. Clin. Nutr., (1988), 42: 81-86.

"Review of Current Practices in Management of Inherited Disorders of Amino Acid Metabolism in Western Europe", Human Nutrition: Applied Nutrition (1986), 40A, Suppl. 1, 61-69.

"Diet Treatment of PKU UAB No. 46", Commonwealth Agricultural Bureau (1980).

"Phenylketonuria", Ann. Rev. Nutr. (1987), 7:117-135.

Observations by a third party.

Kecskemethy et al., "The Use of Gelatin Capsules for Ingestion of Formula in Dietary Treatment of Maternal Phenylketonuria", J. Inher. Metab. Dis., vol. 16, 1993, pp. 111-118.

Kitagawa et al., "Treatment of Phenylketonuria with a Formula Consisting of Low-Phenylalanine Peptide", Enzyme, vol. 38, 1987, pp. 321-327.

\* cited by examiner

*Primary Examiner*—Helen Pratt

(74) *Attorney, Agent, or Firm*—Bell, Boyd & Lloyd LLC

(57) **ABSTRACT**

A nutritional formula for PKU patients. The nutritional formula has, as a protein source, a mixture of caseino-glycomacropeptide and complementary essential amino acids other than Phe to provide a balanced amino acid profile. Vitamins and minerals sufficient to meet daily requirements are also included. When used as a complete diet, the nutritional formula includes a carbohydrate source and a fat source. However the nutritional formula may also be used as a protein supplement in which case the carbohydrate source and the fat source may be omitted. The nutritional formula has a pleasant taste.

**12 Claims, No Drawings**